Adalimumab
Oct 28, 2022
HUMIRA Biosimilars in the US: The Talk of the Psoriatic Arthritis Treatment Market
Psoriatic arthritis (PsA) is a type of chronic inflammatory arthritis that affects approximately 1 in every 10 people with psoriasis. According to the National Psoriasis Foundation, psoriasis is most common in adults aged 30 to 50. However, psoriatic arthritis can develop at any age, including children. Accordin...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
